Doxorubicin Market
Doxorubicin Market Study by Lyophilized Doxorubicin Powder and Doxorubicin Solutions for Breast, Prostate, Ovarian, Lung, Bladder, & Stomach Cancer, and Leukemia from 2024 to 2034
Analysis of Doxorubicin Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Doxorubicin Market Outlook (2024 to 2034)
The global doxorubicin market is approximated at a value of US$ 940.5 million in 2024 and is forecasted to expand at a CAGR of 6.8% to reach US$ 1.81 billion by the end of 2034.
Introduction of nanaomaterials in cancer treatment is one of the notable doxorubicin market trends. The rising cases of cancer across the globe are primarily driving the demand for chemotherapy medications. Some of the widely used cancer medications are adriamycin, docetaxel, cyclophosphamide, cisplatin, and etoposide.
Cancer is one of the leading causes of death across the world and doxorubicin is used as the first line of treatment for it. Doxorubicin is used as chemotherapeutic drug since 1960s. Doxorubicin is witnessing a widespread used for the treatment of bone sarcomas and soft tissues, and cancer related to bladder, ovary, breast, and thyroid. Doxorubicin intercalate within DNA base pairs, leading to breakage of DNA Strands and further inhibition of DNA and RNA synthesis.
Anthracyclines, including doxorubicin (Adriamycin®) and daunorubicin (Daunomycin, Cerubidine®) were first used as antibacterial agents and were derived from the fungus Streptococcus peucetius. The ongoing research activities and increasing initiatives from the respective governments in the North American region to increase awareness about cancer are expected to generate lucrative opportunities for doxorubicin vendors. This region is set to lead the global market in terms of revenue share throughout the forecast period.
- North America is estimated to account for 35.3% of the global doxorubicin market share in 2024.
- According to World Health Organization, cancer is the second-most cause of death in the European region.
- The Western Europe doxorubicin market size is anticipated to reach US$ 298.2 million by 2034.
The South Asia & Pacific and East Asia markets are also anticipated to offer lucrative revenue opportunities for doxorubicin suppliers owing to rising healthcare expenditures in these regions.
- Sales of doxorubicin drugs are foreseen to increase at a CAGR of 6.9% during the next 10 years in East Asia.
| Report Attribute | Detail |
|---|---|
| Doxorubicin Market Size (2024E) | US$ 940.5 Million |
| Forecasted Market Value (2034F) | US$ 1.81 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.8% CAGR |
| South Korea Market Value (2034F) | US$ 74.7 Million |
| Doxorubicin Solution Demand Growth (2024 to 2034) | 6.6% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors are Influencing Sales of Doxorubicin across the World?
“Rising Prevalence and Awareness of Cancer Driving Need for Advanced Anti-Drugs”
- According to the World Health Organization, new cancer cases are expected to increase over 30 million by 2050 worldwide.
Rising cancer awareness is resulting in surge in number of diagnostic testing such as biomarkers, further contributing to the sales of anti-cancer drugs. The use of Doxil for metastatic breast cancer treatment is increasing. Several studies conclude that no one drug or therapy can be effective to cure cancer. Thus, to overcome this situation doctors make use of cancer immunotherapy procedure. To remove cancer tumor majority of time surgical treatment procedure is applied. However, novel delivery approaches to cancer therapeutics are leading to the development of peptide-based drugs for cancer treatment.
“Introduction of Nanotechnology to Boost Efficiency of Cancer Therapeutics”
Integration of nanotechnology in cancer treatment is set to boost the effectiveness of doxorubicin drugs. This technology makes use of nanoparticles (NPs) from 1 to 100nm to detect cancer. Nano-medicine reaches the target location due to its small size and high surface volume ratio and effectively offers therapeutic benefits without any negative effects.
- Several clinical trials related to nano-tailored doxorubicin are under process. According to a recent report by ClinicalTrials.gov, the combination of liposomal Dox with microwave thermotherapy is expected to kill numerous tumor cells. It works according to high heat mechanism. The cancer cells are killed by heating them to several degrees above body temperature.
What Limitations Can Lower Adoption of Doxorubicin Drugs?
“Side Effects Associated with Use of Doxorubicin”
Doxorubicin or Dox can cause several side effects related to cardiotoxicity, gastrointestinal issues, and myelosuppression. These adverse effects can deter the use of doxorubicin for cancer treatment.
Healthcare experts and scientists should majorly focus on overcoming these issues by focusing on research activities. Also, the availability of other alternative treatment options such as immunotherapies and target therapies is expected to hamper the doxorubicin market growth in the coming decade.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Start-up Ecosystem
- Founded in 2021, Odyssey Therapeutics is a United States-based start-up that offers next generation immunomodulators and oncology medicines.
- Frame Therapeutics is a Dutch start-up that offers personalized cancer vaccines to patients. The company operates on their patented technology ‘FramePro’, which aids in the mitigation of cancer cells.
- ElyssaMed is a French start-up that offers antigenic peptides for the treatment of non-small-cell lung cancer (NSCLC) and neuroendocrine tumors. The solution is delivered through an intradermal injection and a cancer vaccine adjuvant.
Country-wise Analysis
Why are Doxorubicin Suppliers Thriving in the United States?
“Early Adoption of Technologically-advanced Cancer Treatment Procedures”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 289.2 Million |
| Growth Rate (2024 to 2034) | 8.1% CAGR |
| Projected Value (2034F) | US$ 632.5 Million |
The United States is the most lucrative market for doxorubicin on a global scale and this can be attributed to the increasing incidence of multiple cancers, the presence of advanced healthcare infrastructure, and rising awareness of cancer treatments. Supportive government initiatives and rapid adoption of advanced treatments are also expected to provide lucrative opportunities for doxorubicin manufacturers. The United States Doxorubicin companies are focusing on development of new products to maximize their revenues and increase their market presence.
- In September 2020, Zydus Cadila, a leading name in the doxorubicin market, announced that it had received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome injection by the United States Food and Drug Administration.
What is the Demand Outlook for Doxorubicin in Japan?
“Ongoing Clinical Trials Will Offer Lucrative Opportunities for Doxorubicin Suppliers”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 49.9 Million |
| Growth Rate (2024 to 2034) | 2.3% CAGR |
| Projected Value (2034F) | US$ 62.5 Million |
- According to the Economist Report, Japan has a high number of cancer survivors compared to the total national population.
The most common cancer cases among Japanese patients are related to prostate, stomach, breast, and lungs. Japan is advancing in the field of cancer treatment. The ongoing research and development activities in Japan regarding the use of liposomal doxorubicin are set to increase the overall market growth.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which Type of Cancer Accounts for High Consumption of Doxorubicin?
“Rising Cases of Breast Cancer Driving Consumption of Doxorubicin Chemotherapy Medications”
| Attribute | Breast Cancer |
|---|---|
| Segment Value (2024E) | US$ 424.7 Million |
| Growth Rate (2024 to 2034) | 8% CAGR |
| Projected Value (2034F) | US$ 919 Million |
The world is witnessing a substantial increase in the incidence of breast cancer and this trend is anticipated to majorly influence doxorubicin sales across the world. Doxorubicin for breast cancer treatment is gaining popularity.
Adriamycin is used as a chemotherapy drug for breast cancer treatment. Adriamycin chemotherapy or doxorubicin chemotherapy damages the genes of cancer cell and effectively stops their reproduction.
Which is the Prime Distribution Channel for Doxorubicin?
“Availability of Advanced Medications Allow Hospital Pharmacies to Hold Leading Market Share”
| Attribute | Hospital Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 428.8 Million |
| Growth Rate (2024 to 2034) | 7.2% CAGR |
| Projected Value (2034F) | US$ 862.7 Million |
In healthcare settings pharmacies plays a vital role in providing all the latest medicine and therapeutics. Hospital pharmacies are set to hold a major market share throughout the forecast period. Cancer patients prefer hospitals for treatment due to the presence of advanced technologies and skilled experts. The presence of pharmacies in the hospital settings makes convenient and quick access to medications for target patients. Furthermore, the pharmacies in the hospital are equipped with skilled staffs such as pharmacists and healthcare professionals who possess adequate knowledge of medicines and diseases.
Competitive Landscape
Key players in the doxorubicin market are investing in R&D activities to launch novel medications. The introduction of advanced cancer solutions increases their market position and revenue shares. They are also employing strategies such as mergers, acquisitions, and collaborations to increase their product offerings.
- In 2024 Johnson & Johnson completed the acquisition of Ambrx. This acquisition is expected to strengthen the Johnson & Johnson’s commitment to innovation in prostate cancer and lead to the development of next-generation antibody drugs and targeted oncologic therapeutics.
Key Segments of Doxorubicin Market Research
-
By Formulation :
- Lyophilized Doxorubicin Powder
- Doxorubicin Solutions
-
By Cancer Type :
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Lung Cancer
- Bladder Cancer
- Stomach Cancer
- Leukemia
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
- FAQs -
How big is the doxorubicin market in 2024?
The global doxorubicin market is calculated at US$ 940.5 million for 2024.
What is the sales outlook for doxorubicin for 2034?
The market for doxorubicin is projected to reach US$ 1.81 billion by 2034.
What is the estimated demand growth for the global market?
Demand for doxorubicin is foreseen to rise at a CAGR of 6.8% from 2024 to 2034.
Which type of doxorubicin is widely consumed?
Sales of lyophilized doxorubicin powder are forecasted to reach US$ 1.07 billion by 2034.
Which are the alternative drugs to doxorubicin?
Some of the drug alternatives include Verzenio (abemaciclib) and Ibrance (palbociclib).
Who are the well-known manufacturers of doxorubicin?
Pfizer Inc., Reddy’s Laboratories Ltd., Changzhou Kinyond Pharmaceutical Co. Ltd., and Janssen-Cilag Pty Limited are leading producers of doxorubicin.
Doxorubicin Market